Rhonda Patrick· PhD
Recombinant soluble ACE2 reduced SARS-CoV-2 infection in engineered human organoid tissues.
Verbal pushback — no audited source on record.
81
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Recombinant soluble ACE2 reduced SARS-CoV-2 infection in engineered human organoid tissues.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
in fact a new study found that human recombinant soluble ace to reduce the Czar's Kove to infection in engineered human organ oeid tissues this is because the soluble ace 2 is thought to bind to the SARS cope to virus and prevent it from infecting the cells